The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Travel, Accommodations, Expenses - Bristol-Myers Squibb
Combination immunotherapy with ipilimumab and nivolumab in patients with advanced biliary tract cancers.
 
Oliver Klein
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Damien Kee
No Relationships to Disclose
 
Adnan Nagrial
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Roche
Research Funding - Akeso Biopharma (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst)
 
Ben Markman
Travel, Accommodations, Expenses - Akeso Biopharma
 
Craig Underhill
Research Funding - Bristol-Myers Squibb (Inst)
 
Michael Michael
Consulting or Advisory Role - Ipsen; Merck
Travel, Accommodations, Expenses - Novartis
 
Caroline Lum
No Relationships to Disclose
 
Andreas Behren
No Relationships to Disclose
 
Jodie Palmer
Stock and Other Ownership Interests - Avecho
 
Niall C. Tebbutt
Honoraria - Amgen; Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Roche
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bayer; Roche
 
Matteo S. Carlino
Honoraria - Bristol-Myers Squibb; MSD; Novartis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; IDEAYA Biosciences; MSD; Novartis; Pierre Fabre; Roche
 
Jonathan S. Cebon
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Novartis; Roche (Inst)
Consulting or Advisory Role - Amgen (Inst); Amgen (Inst); Bionomics; Bionomics (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); MSD (Inst); Novartis; Novartis (Inst); Novartis (Inst); Novartis (Inst)
Research Funding - CSL Behring (Inst); GlaxoSmithKline (Inst)
Patents, Royalties, Other Intellectual Property - GlaxoSmithKline
Expert Testimony - Bristol-Myers Squibb